4 results about "Corpus callosum" patented technology

An automatic calculation method of gray-to-white-matter ratio for head computed tomography of patients with cardiac arrest is disclosed and includes an image registration step, a K-means segmentation step, a segmentation refinement step and a GWR calculation step. Measure the gray-white-matter ratio through brain computed tomography early after cardiac arrest to automatically identify the corpus callosum, caudate nucleus, putamen, and posterior branch of the internal brain cyst. It is a 3D three-dimensional structure rather than a manually selected flat circular area to evaluate the effectiveness of predicting neurological prognosis at discharge.

Abnormal activity in the brain can be detected by identifying changes in tissue excitability measured in response to stimulation of fiber tracts such as the corpus callosum. A stimulating electrode contact can apply a stimulation to the fiber tract, which can have one or more terminals to a cortex of a patient's brain, and a recording electrode contact positioned in the fiber tract and / or the cortex to record a tissue excitability response to the stimulation. A controller can receive the tissue excitability response from the at least one recording electrode, identify a parameter of the tissue excitability response, and predict the abnormal activity in the patient's brain based on the parameter being different from a baseline for the parameter. When an abnormal activity is predicted the patient can be alerted to start a therapy and / or a therapy can be applied in closed loop manner by a connected therapy device.

A chimeric non-human mammal disease model, wherein (1) at least 30% of all the glial cells in the corpus callosum of the chimeric non-human mammal are human glial cells, and / or (2) at least 5% of all of the glial cells in the white matter of the brain and / or brain stem of the chimeric non-human mammal are human glial cells, and wherein the human glial cells comprise a combination of a first group of human glial cells tagged with a first label and a second group of human glial cells tagged with a second label that is distinguishable from the first label.

A chimeric non-human mammal disease model, wherein (1) at least 30% of all the glial cells in the corpus callosum of the chimeric non-human mammal are human glial cells, and / or (2) at least 5% of all of the glial cells in the white matter of the brain and / or brain stem of the chimeric non-human mammal are human glial cells, and wherein the human glial cells comprise a combination of a first group of human glial cells tagged with a first label and a second group of human glial cells tagged with a second label that is distinguishable from the first label.